Needham & Company LLC Reiterates Hold Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “hold” rating reissued by equities researchers at Needham & Company LLC in a research note issued on Wednesday, AnalystRatings.com reports.

A number of other research analysts have also recently weighed in on the company. BidaskClub cut BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, October 4th. ValuEngine cut BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, November 4th. Zacks Investment Research cut BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of BioCryst Pharmaceuticals in a report on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. BioCryst Pharmaceuticals has an average rating of “Hold” and an average target price of $9.64.

BCRX stock opened at $2.03 on Wednesday. BioCryst Pharmaceuticals has a twelve month low of $1.95 and a twelve month high of $9.95. The company has a quick ratio of 1.43, a current ratio of 1.44 and a debt-to-equity ratio of 2.38. The stock has a market cap of $224.19 million, a P/E ratio of -2.07 and a beta of 1.86. The business’s 50-day moving average price is $2.53 and its 200-day moving average price is $3.71.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.03). BioCryst Pharmaceuticals had a negative net margin of 1,091.44% and a negative return on equity of 371.33%. The company had revenue of $1.78 million for the quarter, compared to analysts’ expectations of $4.54 million. On average, equities research analysts expect that BioCryst Pharmaceuticals will post -1.23 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. purchased a new position in BioCryst Pharmaceuticals in the 3rd quarter worth approximately $466,000. California Public Employees Retirement System lifted its holdings in BioCryst Pharmaceuticals by 17.3% in the 3rd quarter. California Public Employees Retirement System now owns 140,314 shares of the biotechnology company’s stock worth $402,000 after purchasing an additional 20,693 shares in the last quarter. Rhumbline Advisers lifted its holdings in BioCryst Pharmaceuticals by 8.4% in the 3rd quarter. Rhumbline Advisers now owns 175,062 shares of the biotechnology company’s stock worth $502,000 after purchasing an additional 13,631 shares in the last quarter. UBS Group AG lifted its holdings in BioCryst Pharmaceuticals by 331.0% in the 2nd quarter. UBS Group AG now owns 2,202,794 shares of the biotechnology company’s stock worth $8,349,000 after purchasing an additional 1,691,681 shares in the last quarter. Finally, University of Notre Dame DU Lac purchased a new position in BioCryst Pharmaceuticals in the 2nd quarter worth approximately $1,854,000. 90.67% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Further Reading: What is a back-end load?

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.